Watchlist Price Alert

Precision BioSciences Inc... (DTIL)

NASDAQ: DTIL · Real-Time Price · USD

5.83

0.11 (1.92%)

At close: May 02, 2025, 3:59 PM

5.75

-1.46%

After-hours: May 02, 2025, 04:05 PM EDT

1.92% (1D)

Bid	5.5
Market Cap	61.56M
Revenue (ttm)	68.7M
Net Income (ttm)	7.17M
EPS (ttm)	0.97
PE Ratio (ttm)	6.02
Forward PE	-1.06
Analyst	Buy

Ask	6.39
Volume	106,412
Avg. Volume (20D)	156,932
Open	5.73
Previous Close	5.72
Day's Range	5.65 - 5.92
52-Week Range	3.61 - 13.44
Beta	1.58

About DTIL

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is i...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 28, 2019

Employees 108

Stock Exchange NASDAQ

Ticker Symbol DTIL

Website https://www.precisionbiosciences.com

Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for DTIL stock is "Buy." The 12-month stock price forecast is $47, which is an increase of 705.48% from the latest price.

Stock Forecasts

Next Earnings Release

Precision BioSciences Inc. is scheduled to release its earnings on May 16, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 weeks ago

+23.77%

Precision BioSciences shares are trading higher af... Unlock content with Pro Subscription

1 month ago

-11%

Precision BioSciences shares are trading lower following a Q4 EPS miss.

News

3 days ago · businesswire.com

Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...

5 days ago · businesswire.com

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

2 weeks ago · zacks.com

DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up

Precision BioSciences stock soars 24% as the FDA grants the Fast Track designation to its PBGENE-HBV gene therapy for potentially curing chronic hepatitis B.

Precision BioSciences (DTIL) came out with a quarterly loss of $3.20 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $3.35 per share a year ago.